Movement Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MVM001 MIFTS: 62	Movement Disease Categories: Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Movement Disease

MalaCards integrated aliases for Movement Disease:

Name: Movement Disease ¹¹ ¹⁴

Movement Disorders ⁵³ ⁴¹ ⁴³ ⁷¹ ³³

Movement Disorder ²⁸ ⁵ ¹⁴ ¹⁶ ⁷⁵

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the nervous system

Movement disorders

Movement disorders, unspecified

Other specified movement disorders

Nutritional or toxic disorders of the nervous system

Neurological disorders due to toxicity

Movement disorders due to toxicity

External Ids:

Disease Ontology ¹¹ DOID:480

MeSH ⁴³ D009069

NCIt ⁴⁹ C116757

SNOMED-CT ⁶⁸ 60342002

EFO ¹⁶ EFO_0004280

ICD11 ³³ 1462849226 384289569 384289569/other more

UMLS ⁷¹ C0026650

Sources

Summaries for Movement Disease

MedlinePlus: ⁴¹ Movement disorders are neurologic conditions that cause problems with movement, such as: Increased movement that can be voluntary (intentional) or involuntary (unintended) Decreased or slow voluntary movement There are many different movement disorders. Some of the more common types include: Ataxia, the loss of muscle coordination Dystonia, in which involuntary contractions of your muscles cause twisting and repetitive movements. The movements can be painful. Huntington's disease, an inherited disease that causes nerve cells in certain parts of the brain to waste away. This includes the nerve cells that help to control voluntary movement. Parkinson's disease, which is disorder that slowly gets worse over time. It causes tremors, slowness of movement, and trouble walking. Tourette syndrome, a condition which causes people to make sudden twitches, movements, or sounds (tics) Tremor and essential tremor, which cause involuntary trembling or shaking movements. The movements may be in one or more parts of your body. Causes of movement disorders include: Genetics Infections Medicines Damage to the brain, spinal cord, or peripheral nerves Metabolic disorders Stroke and vascular diseases Toxins Treatment varies by disorder. Medicines can cure some disorders. Others get better when an underlying disease is treated. Often, however, there is no cure. In that case, the goal of treatment is to improve symptoms and relieve pain.

MalaCards based summary: Movement Disease, also known as movement disorders, is related to dystonia 11, myoclonic and dystonia 12, and has symptoms including ataxia, tremor and myoclonus. An important gene associated with Movement Disease is BCS1L (BCS1 Homolog, Ubiquinol-Cytochrome C Reductase Complex Chaperone), and among its related pathways/superpathways are Neuroscience and Rett syndrome causing genes. The drugs Amantadine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and subthalamic nucleus, and related phenotypes are nervous system and homeostasis/metabolism

Disease Ontology: ¹¹ A brain disease that is characterized by a clinical syndrome of either hyperkinetic movement or hyperkinetic movement unrelated to weakness or spasticity.

Wikipedia: ⁷⁵ Movement disorder refers to any clinical syndrome with either an excess of movement or a paucity of... more...

Sources

Related Diseases for Movement Disease

Diseases in the Movement Disease family:

Rare Movement Disorder

Diseases related to Movement Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1115)

#	Related Disease	Score	Top Affiliating Genes
1	dystonia 11, myoclonic	32.5	TOR1A SGCE GCH1 ATP1A3
2	dystonia 12	32.5	TOR1A SGCE SCN2A PRKN PINK1 PARK7
3	dystonia 3, torsion, x-linked	32.5	TOR1A SGCE GCH1 ATP1A3
4	parkinson disease, late-onset	32.5	TOR1A SNCA SLC6A3 PRKN PINK1 PARK7
5	parkinsonism	32.4	TOR1A TBC1D24 SNCA SLC6A3 PRKN PINK1
6	essential tremor	32.4	SNCA SLC6A3 PRKN LRRK2 GBA1
7	tremor	32.4	SNCA PRKN LRRK2 LOC106627981 GBA1
8	neurodegeneration with brain iron accumulation	32.4	TOR1A SNCA SLC6A3 PRKN PINK1 PARK7
9	gaucher's disease	32.3	SNCA PRKN PINK1 PARK7 LRRK2 LOC106627981
10	dementia, lewy body	32.2	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
11	cervical dystonia	32.2	TOR1A SLC6A3 SGCE PANK2 GCH1 ATP1A3
12	kuru	32.1	SNCA SCN2A HTT
13	dystonia	32.1	TOR1A TBC1D24 SNCA SLC6A3 SGCE PRKN
14	choreatic disease	32.1	TOR1A SNCA SLC6A3 SGCE PRKN PINK1
15	supranuclear palsy, progressive, 1	32.1	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
16	dystonia 1, torsion, autosomal dominant	32.1	TOR1A SGCE GCH1
17	sleep disorder	31.6	SNCA SLC6A3 LRRK2 GBA1
18	postencephalitic parkinson disease	31.4	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
19	dementia	31.3	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
20	epilepsy	31.3	TBC1D24 SLC6A3 SGCE SCN2A GNAO1 ATP1A3
21	multiple system atrophy 1	31.2	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
22	rem sleep behavior disorder	31.1	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
23	focal dystonia	31.1	TOR1A SLC6A3 SGCE PRKN PANK2 GCH1
24	early infantile epileptic encephalopathy	31.1	TBC1D24 SCN2A GNAO1 CLCN6 ATP1A3
25	kufor-rakeb syndrome	31.0	SNCA PRKN PINK1 PARK7 PANK2 LRRK2
26	hereditary spastic paraplegia	31.0	SNCA PRKN PINK1 PANK2 LRRK2 HTT
27	focal hand dystonia	31.0	TOR1A SGCE GCH1
28	prion disease	31.0	SNCA SCN2A HTT
29	parkinson disease 4, autosomal dominant	31.0	SNCA SLC6A3 GBA1
30	speech disorder	30.9	SLC6A3 LOC106627981 GBA1 CLCN6
31	striatonigral degeneration	30.9	SNCA SLC6A3 LRRK2
32	alternating hemiplegia of childhood	30.9	TOR1A TBC1D24 SGCE SCN2A GCH1 ATP1A3
33	frontotemporal dementia	30.9	SNCA PRKN PINK1 PARK7 LRRK2 HTT
34	benign familial infantile epilepsy	30.9	SCN2A GNAO1 CLCN6 ATP1A3
35	vascular parkinsonism	30.9	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
36	neurodegeneration with brain iron accumulation 1	30.8	TOR1A SNCA PANK2
37	parkinson disease 2, autosomal recessive juvenile	30.8	SNCA PRKN PINK1 PARK7 LRRK2
38	early-onset parkinson's disease	30.7	SNCA SLC6A3 PRKN PINK1 PARK7 PANK2
39	developmental and epileptic encephalopathy	30.7	TBC1D24 SCN2A GNAO1 ATP1A3
40	toxic encephalopathy	30.7	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
41	gaucher disease, type i	30.7	SNCA PRKN PINK1 PARK7 LRRK2 LOC106627981
42	autosomal dominant cerebellar ataxia	30.7	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2
43	spasmodic dystonia	30.7	TOR1A SGCE PANK2 GCH1 ATP1A3
44	oromandibular dystonia	30.7	TOR1A SGCE PANK2 GCH1 ATP1A3
45	peripheral nervous system disease	30.7	SNCA SCN2A PRKN PINK1 PARK7 LRRK2
46	blepharospasm	30.7	TOR1A SGCE PANK2 GCH1 ATP1A3
47	segmental dystonia	30.7	TOR1A SGCE GCH1 ATP1A3
48	dystonia, dopa-responsive	30.7	TOR1A SGCE GCH1 ATP1A3
49	machado-joseph disease	30.7	SNCA SLC6A3 PRKN LRRK2 HTT
50	multifocal dystonia	30.7	TOR1A SGCE GCH1 ATP1A3

Graphical network of the top 20 diseases related to Movement Disease:

Sources

Symptoms & Phenotypes for Movement Disease

UMLS symptoms related to Movement Disease:

ataxia; tremor; myoclonus; back pain; involuntary movements; dystonia; headache; syncope; athetosis; clumsiness; cogwheel rigidity; torticollis; pain; pseudobulbar signs; myokymia; muscle fibrillation; chronic pain; sciatica; asterixis; seizures; vertigo/dizziness; sleeplessness; muscle cramp; symptoms; spasm; spasmodic torticollis; hyperexplexia; akathisia; leg cramps

MGI Mouse Phenotypes related to Movement Disease:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.45	ATP1A3 CLCN6 GBA1 GCH1 GNAO1 HTT
2	homeostasis/metabolism	MP:0005376	10.41	ATP1A3 BCS1L GBA1 GCH1 GNAO1 HTT
3	growth/size/body region	MP:0005378	10.36	ATP1A3 BCS1L GBA1 GCH1 GNAO1 HTT
4	behavior/neurological	MP:0005386	10.35	ATP1A3 BCS1L CLCN6 GBA1 GCH1 GNAO1
5	cellular	MP:0005384	10.28	BCS1L CLCN6 GBA1 HTT LRRK2 PANK2
6	cardiovascular system	MP:0005385	10.14	GBA1 GCH1 GNAO1 HTT LRRK2 PRKN
7	skeleton	MP:0005390	9.97	GBA1 GNAO1 HTT LRRK2 PARK7 PINK1
8	hematopoietic system	MP:0005397	9.93	ATP1A3 BCS1L GBA1 GNAO1 HTT LRRK2
9	mortality/aging	MP:0010768	9.83	ATP1A3 BCS1L GBA1 GCH1 GNAO1 HTT
10	taste/olfaction	MP:0005394	9.56	HTT PINK1 SLC6A3 SNCA
11	integument	MP:0010771	9.28	ATP1A3 CLCN6 GBA1 GNAO1 HTT LRRK2

Sources

Drugs & Therapeutics for Movement Disease

Drugs for Movement Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Amantadine

Approved

Phase 4

768-94-5

2130

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Iron

Approved

Phase 4

7439-89-6

29936

Cysteine

Approved, Nutraceutical

Phase 4

52-90-4

594 5862

Neurotransmitter Agents

Phase 4

Dopamine Agents

Phase 4

Antiparkinson Agents

Phase 4

Analgesics

Phase 4

Whey Protein

Phase 4

Soy Bean

Phase 4

Anti-Infective Agents

Phase 4

Antiviral Agents

Phase 4

Analgesics, Non-Narcotic

Phase 4

Bifidobacterium

Phase 4

Acidophilus

Phase 4

Sulfalene

Phase 4

Iron Supplement

Phase 4

Mecobalamin

Approved, Investigational

Phase 2, Phase 3

13422-55-4

Hydroxocobalamin

Approved

Phase 2, Phase 3

13422-51-0

15589840 44475014

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

59-30-3

6037

Pyridoxine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 2, Phase 3

65-23-6

1054

Cyanocobalamin

Approved, Nutraceutical

Phase 2, Phase 3

68-19-9

24892734 16212801 44176380

Cobalamin

Experimental

Phase 2, Phase 3

13408-78-1

6857388

Folate

Phase 2, Phase 3

Vitamins

Phase 2, Phase 3

Vitamin B9

Phase 2, Phase 3

Vitamin B6

Phase 2, Phase 3

Trace Elements

Phase 2, Phase 3

Vitamin B12

Phase 2, Phase 3

Vitamin B Complex

Phase 2, Phase 3

Vitamin B 6

Phase 2, Phase 3

Vitamin B 12

Phase 2, Phase 3

Micronutrients

Phase 2, Phase 3

Dopamine agonists

Phase 2, Phase 3

Pyridoxal

Experimental, Nutraceutical

Phase 2, Phase 3

66-72-8

1050

Entacapone

Approved, Investigational

Phase 2

130929-57-6

5281081

Carbidopa

Approved

Phase 2

28860-95-9

34359 38101

Pramipexole

Approved, Investigational

Phase 2

104632-26-0, 104632-25-9, 104632-28-2

4885 119570 59868

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Istradefylline

Approved, Investigational

Phase 2

155270-99-8

198792 5311037

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Levodopa

Approved

Phase 2

59-92-7, 63-84-3

6047

Ketamine

Approved, Vet_approved

Phase 2

6740-88-1, 1867-66-9

3821

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 2

1401-55-4

16129878 16129778

Midazolam

Approved, Illicit

Phase 2

59467-70-8

4192

Haloperidol

Approved

Phase 2

52-86-8

3559

Propranolol

Approved, Investigational

Phase 2

318-98-9, 525-66-6

62882 4946

Glutamic acid

Approved, Nutraceutical

Phase 2

56-86-0

33032

Aspartic acid

Approved, Nutraceutical

Phase 2

56-84-8

5960

Interventional clinical trials:

(show top 50) (show all 229)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function	Completed	NCT01662414	Phase 4
2	The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia	Completed	NCT00950196	Phase 4	amantadine sulphate
3	Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study	Recruiting	NCT04871464	Phase 4	Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules
4	Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder	Enrolling by invitation	NCT04610827	Phase 4	Ferrous sulfate
5	Effectiveness of Vojta Therapy in Motor Development of Preterm Children	Unknown status	NCT01838278	Phase 3
6	Effect of Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics	Unknown status	NCT03790345	Phase 2, Phase 3	Pyridoxine;Cobalamin;Placebo Oral Tablet
7	An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis	Completed	NCT01550484	Phase 2, Phase 3	18F-AV-133
8	A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)	Terminated	NCT02960217	Phase 3	UX007;Placebo
9	Improving Treatment of People With Movement Disorders in the Middle East	Unknown status	NCT01466296	Phase 2
10	Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia	Unknown status	NCT00331669	Phase 2
11	Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease	Completed	NCT03295786	Phase 1, Phase 2	Cerebral Dopamine Neurotrophic Factor
12	A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)	Completed	NCT00537017	Phase 2	Preladenant;L-dopa;Other Parkinson's Disease treatments
13	A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2002	Completed	NCT03775538	Phase 1, Phase 2	Cerebral Dopamine Neurotrophic Factor
14	A Randomized, Double Blind, Placebo-Controlled, Crossover, Proof of Concept Study to Evaluate the Effectiveness and Safety of Carisbamate in the Treatment of Essential Tremor	Completed	NCT00524056	Phase 2	Carisbamate;Placebo
15	A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias	Completed	NCT00406029	Phase 2	Preladenant;Placebo;L-dopa;Other Parkinson's Disease treatments
16	Impact of Running Poles on Older Adult Exercise Walking	Completed	NCT00037167	Phase 1, Phase 2
17	Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)	Completed	NCT00036296	Phase 1, Phase 2	talampanel
18	Heart Rate Variability in Response to Metformin Challenge	Completed	NCT02500628	Phase 2	Metformin
19	NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease	Completed	NCT00001929	Phase 2	Eliprodil
20	Robot Therapy for Rehabilitation of Hand Movement After Stroke	Completed	NCT04536987	Phase 2
21	An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	Completed	NCT01491932	Phase 2	AFQ056
22	12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	Completed	NCT01385592	Phase 2	AFQ056;Placebo
23	13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	Completed	NCT01491529	Phase 2	AFQ056;Placebo
24	A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease	Completed	NCT00199433	Phase 2	Istradefylline (KW-6002)
25	Phase II Trial of Non-Invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders	Recruiting	NCT05155059	Phase 2
26	A Long-Term Follow-up Safety Study for Patients With Idiopathic Parkinson's Disease (PD) Implanted With the DDS and/or Who Received Treatment in the Main Study and/or Extension Study	Active, not recruiting	NCT04228653	Phase 1, Phase 2
27	An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging	Not yet recruiting	NCT05636852	Phase 2	Altropane (123I) Injection
28	A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects With Parkinson's Disease	Suspended	NCT04912115	Phase 2	Ketamine;Midazolam
29	Efficacy of SCH 420814 to Reduce the Frequency or Severity of Neuroleptic Induced Akathisia	Terminated	NCT00693472	Phase 2	Preladenant;Placebo;Anticholinergic agents or propanolol;Haloperidol
30	An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa	Completed	NCT03065192	Phase 1	VY-AADC01
31	MR-Guided Functional Ultrasound-Neurosurgery for Movement Disorders	Completed	NCT01698450	Phase 1
32	Neuroleptic Induced Movement Disorders in Older Patients	Completed	NCT00255879	Phase 1	Quetiapine;Risperidone;Olanzapine
33	Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation	Completed	NCT00001663	Phase 1
34	Development of a Robotic Ankle Assist Device to Improve Mobility in Individuals With Movement Disorders	Recruiting	NCT04516343	Phase 1
35	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Terminated	NCT02589340	Phase 1	Buspirone;Placebo
36	The Movement Pattern of Shoulder Complex and the Intervention Effects of Therapeutic Exercise in Patients With Proximal Humerus Fracture	Unknown status	NCT04176692
37	Clinical Trial of Surface EMG Biofeedback for Children With Cerebral Palsy and Associated Movement Disorders	Unknown status	NCT01681888
38	Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)	Unknown status	NCT02696603
39	Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue	Unknown status	NCT02138682		l-123 Ioflupane
40	Metabotropic Receptors For Glutamate Type 3 In Parkinson's Disease: Clinical And Neurophysiological Correlations	Unknown status	NCT03998787
41	Changes of the Neuronal Activity in the Subthalamic Nucleus Under Propofol Sedation During Stereotactic Electrode Implantation.	Unknown status	NCT00355927
42	Müller's Muscle as a New Proprioceptive Organ Evidence From Immunohistochemical Staining and Electron Microscopy to Verify That the Upper Eyelid Müller's Muscle Contains Proprioceptive Innervation for Reflexive Correction of Eyelid Position	Unknown status	NCT03396627
43	Assessment of Movement Skills in Autism Spectrum Disorder	Unknown status	NCT03613051
44	Changes of the Neuronal Activity in the Subthalamic Nucleus Under Remifentanil Sedation During Stereotactic Electrode Implantation	Unknown status	NCT00588926		Remifentanil
45	Local Field Potential Correlates of Motor Behavior and Pathological Signs in Movement Disorders for Development of Closed Loop Stimulation Systems	Unknown status	NCT02115802
46	The Role of Probiotics PS128 in Movement Disorders	Unknown status	NCT03259971
47	Systems Medicine of Mitochondrial and Biochemical Parkinson's Disease and Other Related Movement Disorders	Unknown status	NCT03421899
48	Deep Brain Stimulation in the Treatment of Intractable Movement Disorders ( Parkinson's Disease, Essential Tremors and Dystonia)	Unknown status	NCT03562403
49	The Development of an Artificial Intelligence Platform for Screening and Referral of Cognitive Dysfunction	Unknown status	NCT04236375
50	Periodic Limb Movement Syndrome in Patients With Cerebral Small Vessel Disease: a Clinical and Neuropsychological Study.	Unknown status	NCT04569643

Search NIH Clinical Center for Movement Disease

Cochrane evidence based reviews: movement disorders

Sources

Genetic Tests for Movement Disease

Genetic tests related to Movement Disease:

#	Genetic test	Affiliating Genes
1	Movement Disorder ²⁸

Sources

Anatomical Context for Movement Disease

Organs/tissues related to Movement Disease:

MalaCards : Brain, Spinal Cord, Subthalamic Nucleus, Globus Pallidus, Prefrontal Cortex, Cortex, Eye

Sources

Publications for Movement Disease

Articles related to Movement Disease:

(show top 50) (show all 19063)

#	Title	Authors	PMID	Year
1	Movement disorder caused by FRRS1L deficiency may be associated with morphological and functional disorders in Purkinje cells. ⁶² ⁴¹	Wang R...Zhang W	36330921	2022
2	Characterization of Infants' General Movements Using a Commercial RGB-Depth Sensor and a Deep Neural Network Tracking Processing Tool: An Exploratory Study. ⁶² ⁴¹	Balta D...Della Croce U	36236525	2022
3	Whole-genome sequencing of patients with rare diseases in a national health system. ⁵	Turro E...Ouwehand WH	32581362	2020
4	Two-point discrimination responses in children with idiopathic toe walking: A feasibility fMRI study. ⁴¹	Donne J...Williams C	36373762	2022
5	Coexisting huntingtin and SCA8 repeat expansion: case report of a severe complex neurodegenerative syndrome. ⁵³ ⁶²	Bereznai B...Molnar MJ	20403608	2010
6	Expression profiling in peripheral blood reveals signature for penetrance in DYT1 dystonia. ⁵³ ⁶²	Walter M...Grundmann K	20053375	2010
7	TorsinA and DYT1 dystonia: a synaptopathy? ⁵³ ⁶²	Warner TT...Schiavo G	20298201	2010
8	Novel non-sense GCH1 mutation in a South African family diagnosed with dopa-responsive dystonia. ⁵³ ⁶²	Bardien S...Carr J	19566901	2010
9	Siblings with the adult-onset slowly progressive type of pantothenate kinase-associated neurodegeneration and a novel mutation, Ile346Ser, in PANK2: clinical features and (99m)Tc-ECD brain perfusion SPECT findings. ⁵³ ⁶²	Doi H...Kuroiwa Y	20006850	2010
10	Myoclonus in fraternal twin toddlers: a French family with a novel mutation in the SGCE gene. ⁵³ ⁶²	Thummler S...Perelman S	19147379	2009
11	Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity. ⁵³ ⁶²	Li X...DiFiglia M	19752198	2009
12	Hypoceruloplasminemia-related movement disorder without Kayser-Fleischer rings is different from Wilson disease and not involved in ATP7B mutation. ⁵³ ⁶²	Lirong J...Chunjiu Z	19572946	2009
13	Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies. ⁵³ ⁶²	Korenova M...Stozicka Z	19283467	2009
14	Is psychopathology part of the phenotypic spectrum of myoclonus-dystonia?: a study of a large Dutch M-D family. ⁵³ ⁶²	Foncke EM...Tijssen M	19506430	2009
15	Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. ⁵³ ⁶²	Kurian MA...Maher ER	19478460	2009
16	TorsinA and dystonia: from nuclear envelope to synapse. ⁵³ ⁶²	Granata A...Warner TT	19457118	2009
17	Guanidinoacetate methyltransferase (GAMT) deficiency: late onset of movement disorder and preserved expressive language. ⁵³ ⁶²	O'Rourke DJ...King MD	19388150	2009
18	A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. ⁵³ ⁶²	Allen GF...Heales SJ	19231266	2009
19	Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. ⁵³ ⁶²	Camargos ST...Cardoso F	19205068	2009
20	A common variant in DRD3 receptor is associated with autism spectrum disorder. ⁵³ ⁶²	de Krom M...van Ree JM	19058789	2009
21	Pediatric writer's cramp in myoclonus-dystonia: maternal imprinting hides positive family history. ⁵³ ⁶²	Gerrits MC...Tijssen MA	18571946	2009
22	Striatal [123I] FP-CIT SPECT demonstrates dopaminergic deficit in a sporadic case of Creutzfeldt-Jakob disease. ⁵³ ⁶²	Ragno M...Trojano L	18638039	2009
23	Is malfunction of the ubiquitin proteasome system the primary cause of alpha-synucleinopathies and other chronic human neurodegenerative disease? ⁵³ ⁶²	Bedford L...Mayer RJ	18976704	2008
24	Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. ⁵³ ⁶²	Borland MK...Bennett JP	19114014	2008
25	[Glucose transporter type 1 (GLUT-1) deficiency]. ⁵³ ⁶²	Cano A...Chabrol B	18808765	2008
26	Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. ⁵³ ⁶²	Choi JM...Kim YJ	18704525	2008
27	Myoclonus-dystonia due to maternal uniparental disomy. ⁵³ ⁶²	Guettard E...Roze E	18852357	2008
28	Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. ⁵³ ⁶²	Varrone A...Salvatore M	18283454	2008
29	Clinical use of dopamine transporter imaging in movement disorders: benefits of appropriate use. ⁵³ ⁶²	Lucignani G	18425514	2008
30	Cortical excitability in DYT-11 positive myoclonus dystonia. ⁵³ ⁶²	Sabine Meunier...Marie Vidailhet	18265016	2008
31	Myoclonus-dystonia: significance of large SGCE deletions. ⁵³ ⁶²	Grunewald A...Klein C	18205193	2008
32	[Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies]. ⁵³ ⁶²	Orimo S	18386627	2008
33	Novel GCH1 mutation in a Brazilian family with dopa-responsive dystonia. ⁵³ ⁶²	Camargos ST...Singleton A	18044725	2008
34	Clinical differentiation of genetically proven benign hereditary chorea and myoclonus-dystonia. ⁵³ ⁶²	Asmus F...Chinnery PF	17702043	2007
35	Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. ⁵³ ⁶²	Giovanniello T...Antonozzi I	18058633	2007
36	Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients. ⁵³ ⁶²	Ben-Dor DH...Weizman A	17344033	2007
37	Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegeneration. ⁵³ ⁶²	Kuo YM...Gitschier J	17429753	2007
38	Dopamine transporter binding in smokers and nonsmokers. ⁵³ ⁶²	Newberg A...Mozley PD	17515751	2007
39	[A stiff-legged man with a bizarre gait]. ⁵³ ⁶²	Holmoy T...Vandvik B	17566229	2007
40	Initial clinical experience with [123I]ioflupane scintigraphy in movement disorders. ⁵³ ⁶²	Manoharan P...Bury RF	17398272	2007
41	Progression of tremor and ataxia in male carriers of the FMR1 premutation. ⁵³ ⁶²	Leehey MA...Hagerman PJ	17133502	2007
42	Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia? ⁵³ ⁶²	Fiorio M...Tinazzi M	17105745	2007
43	Impact of bilateral pallidal stimulation on DYT1-generalized dystonia in Japanese patients. ⁵³ ⁶²	Goto S...Kaji R	16830314	2006
44	Size bias of fragile X premutation alleles in late-onset movement disorders. ⁵³ ⁶²	Jacquemont S...Hagerman PJ	16723388	2006
45	PANK2 gene analysis confirms genetic heterogeneity in neurodegeneration with brain iron accumulation (NBIA) but mutations are rare in other types of adult neurodegenerative disease. ⁵³ ⁶²	Matarin MM...Houlden H	16962235	2006
46	Characterization of the l-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder. ⁵³ ⁶²	Cozzi A...Levi S	16822677	2006
47	Parkinson's disease: a rethink of rodent models. ⁵³ ⁶²	Melrose HL...Farrer MJ	16639500	2006
48	Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. ⁵³ ⁶²	Yokoi F...Li Y	16815860	2006
49	Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? ⁵³ ⁶²	Hedrich K...Klein C	16769864	2006
50	Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. ⁵³ ⁶²	Tezenas du Montcel S...French Dystonia Network	16227522	2006

Sources

Genes for Movement Disease

Genes related to Movement Disease (3 elite genes):

(show top 50) (show all 123)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BCS1L	BCS1 Homolog, Ubiquinol-Cytochrome C Reductase Complex Chaperone	Protein Coding	404.3	Pathogenic ⁵ DISEASES inferred ¹⁴	32581362
2	CLCN6	Chloride Voltage-Gated Channel 6	Protein Coding	404.15	Pathogenic ⁵ DISEASES inferred ¹⁴
3	RAB3GAP1	RAB3 GTPase Activating Protein Catalytic Subunit 1	Protein Coding	400	Pathogenic ⁵
4	GBA1	Glucosylceramidase Beta 1	Protein Coding	33.16	Risk factor ⁵ DISEASES inferred ¹⁴
5	GNAO1	G Protein Subunit Alpha O1	Protein Coding	31.53	Likely pathogenic ⁵ DISEASES inferred ¹⁴	32581362
6	SCN2A	Sodium Voltage-Gated Channel Alpha Subunit 2	Protein Coding	31.01	Likely pathogenic ⁵ DISEASES inferred ¹⁴	32581362
7	TBC1D24	TBC1 Domain Family Member 24	Protein Coding	30.26	Likely pathogenic ⁵ DISEASES inferred ¹⁴	32581362
8	LOC106627981	GBA Recombination Region	Functional Element	25	Risk factor ⁵
9	TOR1A	Torsin Family 1 Member A	Protein Coding	19.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14872019 12360559 16830314 (more) 12402271 10871631 9585364 20053375 17105745 19457118 16242683 20298201 12975293
10	SNCA	Synuclein Alpha	Protein Coding	19.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12667059 15890012 16003109 (more) 12900507 16639500 15585343 9749615 18704525 15755676 19205068 18976704 15655259 11334819 19114014
11	SGCE	Sarcoglycan Epsilon	Protein Coding	19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18205193 18571946 19506430 (more) 18265016 16815860 12444570 16227522 18852357 12402271 19147379
12	LRRK2	Leucine Rich Repeat Kinase 2	Protein Coding	18.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16250030 19205068 18704525
13	PINK1	PTEN Induced Kinase 1	Protein Coding	18.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16769864 18704525
14	PRKN	Parkin RBR E3 Ubiquitin Protein Ligase	Protein Coding	17.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15266615 11334819 12972409 (more) 15725358 19205068 18704525
15	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	17.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12971118 17398272 19478460 (more) 12411832 18638039 15791439 18425514 18283454 17515751 15207208
16	PARK7	Parkinsonism Associated Deglycase	Protein Coding	17.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18704525
17	ATP1A3	ATPase Na+/K+ Transporting Subunit Alpha 3	Protein Coding	17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15897512
18	GCH1	GTP Cyclohydrolase 1	Protein Coding	15.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19566901 18044725 15786464
19	PANK2	Pantothenate Kinase 2	Protein Coding	15.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17429753 16962235 20006850
20	HTT	Huntingtin	Protein Coding	15.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20403608 11334819 19752198 (more) 15548484
21	DRD2	Dopamine Receptor D2	Protein Coding	15.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9627325 12497624 15943487 (more) 11256581 12402271
22	GAMT	Guanidinoacetate N-Methyltransferase	Protein Coding	14.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8547310 12597058 12701824 (more) 12889668 16169544 19388150 9322805
23	MAPT	Microtubule Associated Protein Tau	Protein Coding	13.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11470966 11447840 10983715 (more) 19283467 11193179
24	TH	Tyrosine Hydroxylase	Protein Coding	13.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16455579 18386627 18058633
25	FMR1	Fragile X Messenger Ribonucleoprotein 1	Protein Coding	13.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16003114 16493202 16723388 (more) 17133502 15300658
26	DRD3	Dopamine Receptor D3	Protein Coding	13.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19058789 10893495 11179771
27	SLC18A2	Solute Carrier Family 18 Member A2	Protein Coding	12.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17344033 8832701
28	DDC	Dopa Decarboxylase	Protein Coding	12.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10522874 10728198 19231266
29	SNCG	Synuclein Gamma	Protein Coding	12.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9749615
30	FTL	Ferritin Light Chain	Protein Coding	12.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16822677
31	ATP7B	ATPase Copper Transporting Beta	Protein Coding	11.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19572946
32	SLC2A1	Solute Carrier Family 2 Member 1	Protein Coding	11.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16149086 15152356 18808765
33	NKX2-1	NK2 Homeobox 1	Protein Coding	10.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17702043 16028188
34	CP	Ceruloplasmin	Protein Coding	10.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19572946
35	GAD2	Glutamate Decarboxylase 2	Protein Coding	9.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17566229
36	MIR132	MicroRNA 132	RNA Gene	9.28	DISEASES inferred ¹⁴ ¹⁴
37	NRTN	Neurturin	Protein Coding	9.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11891666
38	MIR9-1	MicroRNA 9-1	RNA Gene	8.9	DISEASES inferred ¹⁴ ¹⁴
39	THAP1	THAP Domain Containing 1	Protein Coding	8.7	DISEASES inferred ¹⁴
40	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	8.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12629505
41	ATP13A2	ATPase Cation Transporting 13A2	Protein Coding	8.57	DISEASES inferred ¹⁴
42	MAOB	Monoamine Oxidase B	Protein Coding	8.32	DISEASES inferred ¹⁴
43	GYPE	Glycophorin E (MNS Blood Group)	Protein Coding	8.2	DISEASES inferred ¹⁴
44	SERPINA3	Serpin Family A Member 3	Protein Coding	8.17	DISEASES inferred ¹⁴ ¹⁴
45	CBS	Cystathionine Beta-Synthase	Protein Coding	8.11	DISEASES inferred ¹⁴
46	VIM	Vimentin	Protein Coding	8.07	DISEASES inferred ¹⁴
47	C9orf72	C9orf72-SMCR8 Complex Subunit	Protein Coding	8.05	DISEASES inferred ¹⁴
48	PLA2G6	Phospholipase A2 Group VI	Protein Coding	7.93	DISEASES inferred ¹⁴
49	VPS35	VPS35 Retromer Complex Component	Protein Coding	7.9	DISEASES inferred ¹⁴
50	TARDBP	TAR DNA Binding Protein	Protein Coding	7.83	DISEASES inferred ¹⁴

Sources

Variations for Movement Disease

ClinVar genetic disease variations for Movement Disease:

⁵ (show all 12)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	BCS1L	NM_001079866.2(BCS1L):c.268C>T (p.Arg90Cys)	SNV	Pathogenic Pathogenic	625207	rs369691608	GRCh37: 2:219525978-219525978 GRCh38: 2:218661255-218661255
2	BCS1L	NM_001079866.2(BCS1L):c.518G>A (p.Gly173Asp)	SNV	Pathogenic Pathogenic	625208	rs375876694	GRCh37: 2:219526539-219526539 GRCh38: 2:218661816-218661816
3	CLCN6	NM_001286.5(CLCN6):c.1658A>G (p.Tyr553Cys)	SNV	Pathogenic	974617	rs1644918844	GRCh37: 1:11894424-11894424 GRCh38: 1:11834367-11834367
4	RAB3GAP1	NM_012233.3(RAB3GAP1):c.151-5T>G	SNV	Pathogenic	996741	rs1690127143	GRCh37: 2:135848563-135848563 GRCh38: 2:135090993-135090993
5	TBC1D24	NM_001199107.2(TBC1D24):c.901C>T (p.Gln301Ter)	SNV	Likely Pathogenic	812998	rs1596969013	GRCh37: 16:2547050-2547050 GRCh38: 16:2497049-2497049
6	TBC1D24	NM_001199107.2(TBC1D24):c.605C>T (p.Ser202Leu)	SNV	Likely Pathogenic	207501	rs796053400	GRCh37: 16:2546754-2546754 GRCh38: 16:2496753-2496753
7	SCN2A	NM_001040142.2(SCN2A):c.1270G>T (p.Val424Leu)	SNV	Likely Pathogenic	812987	rs1574567728	GRCh37: 2:166170505-166170505 GRCh38: 2:165313995-165313995
8	GNAO1	NM_020988.3(GNAO1):c.625C>T (p.Arg209Cys)	SNV	Likely Pathogenic	265350	rs886039494	GRCh37: 16:56370674-56370674 GRCh38: 16:56336762-56336762
9	LOC106627981, GBA1	NM_000157.4(GBA1):c.1448T>C (p.Leu483Pro)	SNV	Risk Factor	4288	rs421016	GRCh37: 1:155205043-155205043 GRCh38: 1:155235252-155235252
10	PDZD4	NM_001303512.2(PDZD4):c.10_16del (p.Asn4fs)	DEL	Uncertain Significance	1710147		GRCh37: X:153095738-153095744 GRCh38: X:153830283-153830289
11	ITPR1	NM_001378452.1(ITPR1):c.2477C>T (p.Ser826Phe)	SNV	Uncertain Significance	523421	rs1553686424	GRCh37: 3:4715906-4715906 GRCh38: 3:4674222-4674222
12	TUBA1A	NM_006009.4(TUBA1A):c.455T>A (p.Leu152Gln)	SNV	Uncertain Significance	381536	rs1057521063	GRCh37: 12:49579694-49579694 GRCh38: 12:49185911-49185911

Copy number variations for Movement Disease from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	262562	X	37500000	47300000	Deletion	MAOA	Movement disorder
2	262566	X	37500000	47300000	Deletion	MAOB	Movement disorder

Sources

Expression for Movement Disease

Search GEO for disease gene expression data for Movement Disease.

Sources

Pathways for Movement Disease

Pathways related to Movement Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neuroscience ³	12.14	TOR1A SNCA SCN2A PRKN PINK1 PARK7
2	Rett syndrome causing genes ⁷⁴	11.11	SCN2A HTT GNAO1
3	Alpha-synuclein signaling ⁶¹	10.97	TOR1A SNCA SLC6A3 PRKN PARK7
4	Parkinson's disease pathway ⁷⁴	10.68	SNCA SLC6A3 PRKN PINK1 PARK7 LRRK2

Sources

GO Terms for Movement Disease

Cellular components related to Movement Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth cone	GO:0030426	10.01	TOR1A SNCA PINK1 LRRK2
2	postsynapse	GO:0098794	9.98	SNCA RAB3GAP1 LRRK2 ATP1A3
3	cell projection	GO:0042995	9.91	TOR1A TBC1D24 SNCA SLC6A3 SGCE PRKN
4	synapse	GO:0045202	9.86	ATP1A3 LRRK2 PARK7 PRKN SNCA TBC1D24
5	Lewy body	GO:0097413	9.62	PRKN PINK1
6	axon	GO:0030424	9.53	SNCA SLC6A3 SCN2A PINK1 PARK7 LRRK2
7	inclusion body	GO:0016234	9.43	SNCA LRRK2 HTT
8	obsolete integral component of presynaptic membrane	GO:0099056	9.33	SLC6A3 SCN2A ATP1A3

Biological processes related to Movement Disease according to GeneCards Suite gene sharing:

(show all 37)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of neuron apoptotic process	GO:0043524	10.21	SNCA PRKN PINK1 PARK7 GBA1
2	cellular response to oxidative stress	GO:0034599	10.19	LRRK2 PARK7 PINK1 SNCA
3	response to oxidative stress	GO:0006979	10.16	TOR1A PRKN PINK1 PARK7 LRRK2
4	autophagy	GO:0006914	10.14	GBA1 LRRK2 PARK7 PINK1 PRKN
5	adult locomotory behavior	GO:0008344	10.13	PARK7 PRKN SNCA
6	protein destabilization	GO:0031648	10.11	SNCA PRKN HTT
7	negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	GO:1902236	10	PRKN PARK7 LRRK2
8	regulation of dopamine metabolic process	GO:0042053	9.97	SLC6A3 PRKN
9	negative regulation of hydrogen peroxide-induced cell death	GO:1903206	9.97	PARK7 LRRK2
10	regulation of cellular response to oxidative stress	GO:1900407	9.97	PRKN PINK1
11	regulation of reactive oxygen species metabolic process	GO:2000377	9.97	SNCA PRKN PINK1
12	cellular response to manganese ion	GO:0071287	9.96	PRKN LRRK2
13	protein localization to mitochondrion	GO:0070585	9.96	PRKN LRRK2
14	cellular response to toxic substance	GO:0097237	9.96	PRKN PINK1
15	regulation of protein targeting to mitochondrion	GO:1903214	9.95	PRKN PINK1
16	mitophagy	GO:0000423	9.95	PRKN PINK1 GBA1
17	regulation of locomotion	GO:0040012	9.94	SNCA LRRK2
18	positive regulation of histone deacetylase activity	GO:1901727	9.93	PINK1 LRRK2
19	positive regulation of synaptic vesicle endocytosis	GO:1900244	9.93	TOR1A LRRK2
20	mitochondrion organization	GO:0007005	9.93	BCS1L GBA1 LRRK2 PARK7 PINK1 PRKN
21	positive regulation of mitophagy in response to mitochondrial depolarization	GO:0098779	9.92	PINK1 PRKN
22	regulation of mitochondrial membrane potential	GO:0051881	9.92	PRKN PINK1 PARK7 PANK2
23	negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	GO:1903377	9.91	PRKN PARK7
24	positive regulation of protein lipidation	GO:1903061	9.91	RAB3GAP1 GBA1
25	dopamine biosynthetic process	GO:0042416	9.91	SNCA SLC6A3 GCH1
26	positive regulation of mitochondrial electron transport, NADH to ubiquinone	GO:1902958	9.9	PINK1 PARK7
27	mitochondrion to lysosome transport	GO:0099074	9.89	PRKN PINK1
28	negative regulation of oxidative stress-induced neuron death	GO:1903204	9.89	TBC1D24 PINK1 PARK7
29	regulation of CAMKK-AMPK signaling cascade	GO:1905289	9.88	LRRK2 HTT
30	negative regulation of oxidative stress-induced cell death	GO:1903202	9.88	PRKN PINK1 PARK7
31	negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway	GO:1903384	9.86	PINK1 PARK7
32	positive regulation of autophagy of mitochondrion	GO:1903599	9.85	HTT PARK7 PRKN
33	positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization	GO:1904925	9.79	PINK1 GBA1
34	regulation of synaptic vesicle transport	GO:1902803	9.73	PRKN PINK1 LRRK2
35	negative regulation of neuron death	GO:1901215	9.7	SNCA PRKN PINK1 PARK7 LRRK2 GBA1
36	synaptic transmission, dopaminergic	GO:0001963	9.65	PARK7 PRKN SNCA
37	dopamine uptake involved in synaptic transmission	GO:0051583	9.23	SNCA SLC6A3 PRKN PARK7

Molecular functions related to Movement Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex binding	GO:0044877	9.85	SLC6A3 PRKN PINK1 PARK7 GCH1
2	nucleotide binding	GO:0000166	9.28	TOR1A PINK1 PANK2 LRRK2 GNAO1 GCH1
3	cuprous ion binding	GO:1903136	9.26	SNCA PARK7